Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats

Int J Obes (Lond). 2017 Mar;41(3):381-389. doi: 10.1038/ijo.2016.224. Epub 2016 Dec 7.

Abstract

Background/objectives: The combination of energy dense diets and reduced energy expenditure in modern society has escalated the prevalence of obesity and obesity-related comorbidities. Among these disease states, type-2 diabetics (T2D) are disproportionately associated with obesity, suggesting a shared etiology. In conjunction with defects in hormonal and inflammatory states, obesity and T2D are also characterized by dysbiosis.

Methods: We have recently described the beneficial effects of duodenal nutrient exclusion, as induced by the duodenal endoluminal sleeve (DES); including body weight loss, prevented fat mass accumulation, and improved glucose tolerance in the ZDF rat, a rodent model of obesity and type-2 diabetes (T2D). To assess the relative role of DES on hindgut microbiota in the context of these metabolic changes, we analyzed cecal samples from rats implanted with a duodenal endoluminal sleeve (DES), or a sham control of this procedure. A group of pair-fed (pf) sham controls was also included to account for changes induced by reduced body weight and food intake.

Results: Analysis of hindgut microbiota following DES in the ZDF rat elucidated discrete changes in several microbial populations including a reduction in Paraprevotella family members of the Clostridiales order along with an increase in Akkermansia muciniphila and species of the Allobaculum and Bifidobacterium genera.

Conclusions: Altogether, these observations suggest that like Roux-en Y gastric bypass (RYGB) and Metformin, regulation of gut microbiota may be a contributing factor to the therapeutic effects of DES.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2 / pathology*
  • Disease Models, Animal
  • Duodenum / surgery*
  • Dysbiosis / pathology*
  • Gastric Bypass
  • Gastrointestinal Microbiome* / drug effects
  • Hypoglycemic Agents / pharmacology*
  • Metformin / pharmacology*
  • Obesity / pathology*
  • Rats
  • Rats, Zucker
  • Weight Loss

Substances

  • Hypoglycemic Agents
  • Metformin